VRDNViridian Therapeutics Inc
$19.87
$0.61
(2.98%)
Closed $19.86
$0.01
(0.05%)
After Hours
EarningsAug 6
Mkt Cap$2.26B
Vol1.72M
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Zacks
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...
Benzinga
4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones
As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. $UPC, $NTHI, $DCOY, $VRDN
24-7 Market News
Futures Rise As Dip-Buyers Lift Tech Stocks
Futures Rise As Dip-Buyers Lift Tech Stocks
US equity futures are higher led by Tech as Mag7 leads the group higher and points to a reversal of last week's profit-taking, as traders position for the end of the first half. A shortened week will likely focus on a speech from the Fed's...
Zero Hedge
Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday
U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.read more...
Benzinga
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze...
Business Wire
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor...
Business Wire
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for autoimmune and rare diseases, today...
Business Wire
Viridian Therapeutics (NASDAQ:VRDN) Given "Buy" Rating at Needham & Company LLC
Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday...
MarketBeat
<
1
2
...
>